(Q34620222)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20524722%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

review article

1 reference

title

Cost effectiveness of cytotoxic and targeted therapy for metastatic breast cancer: a critical and systematic review (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20524722%20AND%20SRC:MED&resulttype=core&format=json

cost-effectiveness analysis

4 February 2020

main subject

cytotoxicity

0 references

1 reference

1 reference

metastatic breast cancer

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20524722%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

author name string

Konstantin J Dedes

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20524722%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

Thomas D Szucs

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20524722%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

publication date

1 January 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20524722%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20524722%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

volume

28

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20524722%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20524722%20AND%20SRC:MED&resulttype=core&format=json

4 February 2020

page(s)

629-647

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20524722%20AND%20SRC:MED&resulttype=core&format=json

Chemokines, cytokines and their receptors in Hodgkin's lymphoma cell lines and tissues

4 February 2020

cites work

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F11535560-000000000-00000

Transferability of model-based economic evaluations: the case of trastuzumab for the adjuvant treatment of HER2-positive early breast cancer in the Netherlands.

21 January 2018

1 reference

12 December 2020

Bevacizumab in combination with paclitaxel for HER-2 negative metastatic breast cancer: an economic evaluation

1 reference

12 December 2020

Evaluation of conflict of interest in economic analyses of new drugs used in oncology

1 reference

12 December 2020

Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252.

1 reference

12 December 2020

Transferability of economic evaluations: approaches and factors to consider when using results from one geographic area for another

1 reference

12 December 2020

Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer

1 reference

12 December 2020

Cost-effectiveness analysis of trastuzumab (herceptin) in HER2-overexpressed metastatic breast cancer.

1 reference

12 December 2020

Nab-paclitaxel for breast cancer: a new formulation with an improved safety profile and greater efficacy

1 reference

12 December 2020

Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Patients With Taxane-Resistant Metastatic Breast Cancer

1 reference

12 December 2020

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

1 reference

12 December 2020

Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared With Polyethylated Castor Oil–Based Paclitaxel in Women With Breast Cancer

1 reference

12 December 2020

Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer

1 reference

12 December 2020

Ixabepilone in combination with capecitabine and as monotherapy for treatment of advanced breast cancer refractory to previous chemotherapies

1 reference

12 December 2020

Cost-effectiveness of trastuzumab as adjuvant therapy for early breast cancer: a systematic review

1 reference

12 December 2020

Recommendations of the Panel on Cost-effectiveness in Health and Medicine

1 reference

12 December 2020

Cost-effectiveness analysis of lapatinib in HER-2-positive advanced breast cancer

1 reference

12 December 2020

The biology of erbB-2/neu/HER-2 and its role in cancer

1 reference

12 December 2020

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

1 reference

12 December 2020

A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer: a Hellenic Cooperative Oncology Group study

1 reference

12 December 2020

Metastatic breast cancer: therapeutic options according to molecular subtypes and prior adjuvant therapy

1 reference

12 December 2020

Population-based pharmacoeconomic model for adopting capecitabine/docetaxel combination treatment for anthracycline-pretreated metastatic breast cancer

1 reference

12 December 2020

Cost effectiveness of ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment

1 reference

12 December 2020

Use of quality adjusted life years and life years gained as benchmarks in economic evaluations: a critical appraisal

1 reference

12 December 2020

Trastuzumab--mechanism of action and use in clinical practice

1 reference

12 December 2020

When does quality-adjusting life-years matter in cost-effectiveness analysis?

1 reference

12 December 2020

Reply to the article "A monoclonal antibody against HER-2 (trastuzumab) for metastatic breast cancer: a model based cost-effectiveness analysis", by J. Norum et al. (Ann Oncol 2005; 16: 909-914)

1 reference

12 December 2020

Phase 3 study comparing the use of docetaxel on an every-3-week versus weekly schedule in the treatment of metastatic breast cancer

1 reference

12 December 2020

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group

1 reference

12 December 2020

Economic analysis of albumin-bound paclitaxel for the treatment of metastatic breast cancer

1 reference

12 December 2020

Balancing costs and benefits in cancer therapy and prevention

1 reference

12 December 2020

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

1 reference

12 December 2020

Medical Care Costs and Quality of Life after Randomization to Coronary Angioplasty or Coronary Bypass Surgery

1 reference

12 December 2020

nab-Paclitaxel weekly or every 3 weeks compared to standard docetaxel as first-line therapy in patients with metastatic breast cancer: an economic analysis of a prospective randomized trial

1 reference

12 December 2020

Use of the monoclonal antibody anti-HER2 trastuzumab in the treatment of metastatic breast cancer: a cost-effectiveness analysis

1 reference

12 December 2020

Survival outcome and cost-effectiveness with docetaxel and paclitaxel in patients with metastatic breast cancer: a population-based evaluation

1 reference

12 December 2020

The economic value of innovative treatments over the product life cycle: the case of targeted trastuzumab therapy for breast cancer

1 reference

12 December 2020

A phase I study of the safety and pharmacokinetics of the combination of pertuzumab (rhuMab 2C4) and capecitabine in patients with advanced solid tumors

1 reference

12 December 2020

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

12 December 2020

An economic evaluation of docetaxel and paclitaxel regimens in metastatic breast cancer in the UK.

1 reference

12 December 2020

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

1 reference

12 December 2020

Randomized Phase III Trial of Weekly Compared With Every-3-Weeks Paclitaxel for Metastatic Breast Cancer, With Trastuzumab for all HER-2 Overexpressors and Random Assignment to Trastuzumab or Not in HER-2 Nonoverexpressors: Final Results of Cancer an

1 reference

12 December 2020

Cost-effectiveness analysis of trastuzumab in the adjuvant setting for treatment of HER2-positive breast cancer

1 reference

12 December 2020

Bias in published cost effectiveness studies: systematic review

1 reference

12 December 2020

Economic evaluation of taxane-based first-line chemotherapy in the treatment of patients with metastatic breast cancer in Greece: an analysis alongside a multicenter, randomized phase III clinical trial

1 reference

12 December 2020

Can we cure limited metastatic breast cancer?

1 reference

12 December 2020

Cost-effectiveness analyses of statistically ineffective treatments

1 reference

12 December 2020

Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results

1 reference

12 December 2020

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

1 reference

12 December 2020

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

1 reference

12 December 2020

Personalizing therapy for metastatic breast cancer

1 reference

12 December 2020

A monoclonal antibody against HER-2 (trastuzumab) for metastatic breast cancer: a model-based cost-effectiveness analysis.

1 reference

12 December 2020

Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer

1 reference

12 December 2020

ErbB-2 protein in sera and tumors of breast cancer patients

1 reference

12 December 2020

Therapeutic options for metastatic breast cancer

1 reference

12 December 2020

European perspective on the costs and cost-effectiveness of cancer therapies

1 reference

12 December 2020

HER2 status in breast cancer--an example of pharmacogenetic testing.

1 reference

12 December 2020